Background-Patients with the sleep apnoea/hypopnoea syndrome (SAHS) report improved sleepiness, cognitive function, and psychological well being after continuous positive airway pressure (CPAP) therapy, and it is for these daytime features that CPAP is usually given. However, few randomised or controlled studies exist on the eVects of CPAP on daytime function. Methods-A prospective, randomised, single blind, placebo controlled, crossover trial of daytime function after CPAP was conducted in 23 patients with SAHS, all with >15 apnoeas+hypopnoeas/hour and >2 symptoms of SAHS. All patients spent four weeks on CPAP therapy and four weeks on oral placebo treatment, following randomisation to treatment order. With ethics committee approval, patients were told the placebo tablet might improve upper airway function. Average eVective CPAP use was monitored using hidden time clocks. Assessments of objective and subjective sleepiness, symptoms, cognitive performance, and psychological well being were performed on the last day of each treatment and compared. Results-Objective sleepiness measured by sleep onset latency on the multiple sleep latency test improved with CPAP (mean diVerence from placebo +2.4 min, 95% CI 0.8 to 4.0; p<0.001) as did subjective sleepiness on the Epworth scale (mean diVerence -6, 95% CI -3 to -9; p = 0.001). Symptom total score also fell with CPAP (mean diVerence -1.6, 95% CI -2.2 to -1.0; p<0.001). No determinants of these changes with active treatment were identified, and no significant enhancements to cognitive function or psychosocial well being were found in this small sample. Conclusions-These findings provide further evidence for clinically significant benefits to daytime function from CPAP.
Excessive daytime sleepiness, cognitive deficits, and impaired psychosocial function [1] [2] [3] [4] [5] are major features of the sleep apnoea/hypopnoea syndrome (SAHS), and provide the greatest incentive to seek treatment. The current treatment of choice is continuous positive airway pressure (CPAP) but the evidence for the eYcacy of CPAP has recently been challenged by Wright et al 6 who concluded from a systematic review of the benefits of CPAP in SAHS that "the results . . . do not . . . provide suYciently robust evidence for the eVectiveness of continuous positive airway pressure".
Randomised controlled trials of daytime function after intervention with CPAP are few. 7 8 In one recent report of 32 patients with a wide range of severity of SAHS 7 we observed significant enhancements for objective and subjective sleepiness, cognitive function, psychological well being, and functional status following CPAP therapy. A smaller study in 16 patients with mild SAHS 8 showed no changes in sleepiness but improved symptoms, cognitive performance, and psychosocial well being with CPAP.
We report here a further prospective, randomised, placebo controlled study designed to control for placebo and learning eVects, and conducted in a sample of symptomatic patients with moderate and severe SAHS. The trial tested the hypothesis that sleepiness, cognitive performance, and psychological well being would improve with CPAP, and sought possible determinants of such improvements.
Methods

STUDY PROTOCOL
A prospective series of 23 patients with SAHS completed the single blind, placebo controlled, crossover study of daytime function on CPAP following the previously reported assessment protocol. 7 Entry criteria included >15 apnoeas + hypopnoeas per hour slept on polysomnography, scored by our usual methods, 1 9 in conjunction with two or more of eight symptoms of SAHS (table 1) . 2 Patients with lung disease, neurological disorders, and coexisting sleep disorders or who lived more than 50 miles from the Scottish National Sleep Centre were excluded.
Patients spent four weeks on CPAP (Sullivan APD-1 units, ResCare Ltd, Abingdon, UK) and four weeks on an oral placebo tablet (Glaxo, UK) in random order. The trial was conducted and analysed on an "intention to treat" basis with the randomisation slot of one unavoidable patient withdrawal (due to myocardial infarction during the CPAP limb) filled with the next available recruit. With the permission of the local ethics subcommittee patients were told that the placebo treatment, prescribed as two tablets per night, might improve upper airway function. Patients were advised to use CPAP as long as possible each night, had access to telephone advice and nursing support, and were contacted two weeks into the CPAP treatment limb to manage any problems or side eVects, so optimising compliance.
Before starting treatment patients underwent baseline evaluation on all daytime function tests except the multiple sleep latency test (MSLT) (table 1) in order to reduce subsequent learning eVects, and were educated in the mechanisms of action of CPAP therapy and placebo. All attended for overnight CPAP titration to establish an optimum pressure to reduce hypopnoeas and arousals. During the CPAP treatment period objective CPAP use was monitored with two hidden time clocks, one logging total duration that units were switched on and the second that CPAP was delivered eVectively to the nasal mask, 10 allowing average use rates to be calculated. All measurements in table 1 were repeated on the last day of each treatment period. At the final assessment subjects were asked to rate which treatment they preferred.
ANALYSIS OF DATA
The measurements obtained at assessments during placebo and CPAP treatment periods were compared with alpha significance set at p values of <0.05. Analyses were conducted using repeated measures analysis of variance for continuous normally distributed variables, paired Wilcoxon tests for ordinal and nonnormally distributed data, and McNemar tests for dichotomous variables. Treatment preference was assessed by binomial test. The analysis of variance included treatment type as a within subject factor and treatment order as a between subjects factor. Significant treatment order eVects were managed as recommended 11 by performing unpaired comparisons of first treatment assessments only to evaluate treatment eVects.
Determinants of treatment eVect were sought by entering eVective CPAP use and polysomnographic variables (apnoea/hypopnoea index (AHI), microarousal index, 4% desaturation index, and minimum oxygen saturation, each normalised by log transformation) as covariates in significant analyses of variance. All analyses were conducted using SPSS/PC+.
Results
The mean (SD) age of the 23 patients (two women) was 47 (12) years, with a mean body mass index of 30 (7) kg per m 2 at baseline. Clinical polysomnography yielded an average AHI of 43 (37) per hour slept, 50 (36) microarousals per hour slept, 21 (30) 4% O 2 desaturations per hour slept, and mean minimum oxygen saturation of 77 (13)%.
Thirteen patients were randomised to commence with the placebo treatment and 10 with CPAP therapy. During the CPAP limb, CPAP units were switched on for an average 3.2 (1.9) hours per night and used eVectively for 2.8 (2.0) hours per night. The patient sample available for analysis was reduced to 22 for each of SteerClear and eight-choice reaction time tasks (due to computer malfunction), paced auditory serial addition test (due to a patient's stammer), and Epworth scale (due to the late addition of this measure).
TREATMENT ORDER AND LEARNING EFFECTS
A significant eVect of treatment order was demonstrated for Epworth sleepiness score alone, necessitating in this variable a secondary analysis of treatment eVect. 11 Significant treatment × treatment order interactions, representing learning eVects from first to second treatment assessment, were demonstrated for sleep onset latency on the multiple sleep latency test (MSLT), and scores for SteerClear, rapid visual information processing (RVIP), two second paced auditory serial addition test (PASAT), and Benton visual retention test (BVRT). These learning eVects were controlled by randomised treatment order.
TREATMENT EFFECTS
Mean sleep onset latency from the multiple sleep latency test (MSLT) was significantly higher on CPAP (mean (SD) 9.2 (3.9)) by an average 2.4 min (95% CI 0.8 to 4.0 min; p<0.001) compared with placebo values, reflecting improved objective daytime sleepiness (table 2, fig 1C) approaching the range characterised as normal. 12 Subjective sleepiness (Epworth scale (fig 1B) ) was also reduced by six points (95% CI -3 to -9; p = 0.001) with CPAP, the mean placebo rating (12 (4)) falling within the pathological range and average CPAP score (6 (3)) within normal limits. 3 The total symptom score fell by a mean 1.6 (95% CI -2.2 to -1.0; p<0.001) on CPAP compared with placebo ( fig 1A) with two of the eight individual items (snoring and daytime napping) showing significant improvements (p<0.01; fig 2) . Twelve of the 23 patients preferred CPAP treatment, this proportion remaining non-significant (p>0.9). No changes in cognitive performance or psychosocial function with active CPAP treatment were found.
ANALYSES OF COVARIANCE
No significant covariates for these significant treatment eVects were found amongst the putative determinants of eVective CPAP use and polysomnographic severity variables.
Discussion
These 23 patients with moderate and severe SAHS showed improvements in objective sleepiness and symptoms after CPAP similar in scale to those documented in our report in patients with a wide range of severity of SAHS. 7 In addition, self ratings using the Epworth scale showed a substantial reduction in subjective sleepiness with CPAP, similar in scale to that seen in uncontrolled studies of CPAP treatment. 3 The changes in objective and 
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